WO2024231938 - BENZALKONIUM CHLORIDE FREE OPHTHALMIC FORMULATION
National phase entry:
Publication Number
WO/2024/231938
Publication Date
14.11.2024
International Application No.
PCT/IN2023/051120
International Filing Date
30.11.2023
Title **
[English]
BENZALKONIUM CHLORIDE FREE OPHTHALMIC FORMULATION
[French]
FORMULATION OPHTALMIQUE EXEMPTE DE CHLORURE DE BENZALKONIUM
Applicants **
AKUMS DRUGS & PHARMACEUTICALS LIMITED
304, Mohan Place, L.S.C. Block-C, Saraswati Vihar
Delhi 110034, IN
Inventors
JAIN, Sanjeev
Akums Drugs & Pharmaceuticals Limited
304, Mohan Place, LSC, Block-C, Saraswati Vihar
Delhi 110034, IN
GOSWAMI, Manoj
Akums Drugs & Pharmaceuticals Ltd.
304, Mohan Place, LSC, Block-C, Saraswati Vihar
Delhi 110034, IN
MODI, Manu
Akums Drugs & Pharmaceuticals Ltd.
304, Mohan Place, LSC, Block-C, Saraswati Vihar
Delhi 110034, IN
Priority Data
202311033469
11.05.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1049 | |
| EPO | Filing, Examination | 6635 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3910 |
Total: 12763 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides an ophthalmic composition comprising fixed dose combinations of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) wherein the composition is free of benzalkonium chloride (BAK). The ophthalmic composition of the present invention provides a stable aqueous ophthalmic composition comprising fixed dose combination of Brinzolamide and Brimonidine tartate preserved with synergistic combination of EDTA, mannitol, borate and zinc or salts thereof to preserve the composition against microbial growth.[French]
La présente invention concerne une composition ophtalmique comprenant des combinaisons de doses fixes d'inhibiteur(s) d'anhydrase carbonique et d'agoniste(s) alpha-2-adrénergique, la composition étant exempte de chlorure de benzalkonium (BAK). La composition ophtalmique de la présente invention fournit une composition ophtalmique aqueuse stable comprenant une combinaison de doses fixes de Brinzolamide et de tartate de Brimonidine conservée avec une combinaison synergique d'EDTA, de mannitol, de borate et de zinc ou de sels de celui-ci pour préserver la composition contre la croissance microbienne.